There are a lot of moving part with IMU and some do appear to be taking an inordinate time
That " NEO Polem announcement came out last Nov/Dec 2023 ( see attached )
ASX Announcement Dec 6 2023
" New PD1-Vaxx Phase 2 Colorectal Cancer Clinical Trial to Open in UK and Australia • New PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial to commence in 2024 • Approximately 10 sites, 6 in Australia and 4 in the UK with approximately 44 patients to be enrolled in the study over about 18 months • Investigator Sponsored Study (IST) clinical trial to be conducted by the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton in collaboration with Royal Surrey Hospital NHS Foundation Trust and The Australasian Gastro-Intestinal Trials Group (AGITG) • Primary objective is to determine major pathological response rates, a measurement of tumour size, after treating with PD1-Vaxx before surgery to remove any residual tumour also known as neoadjuvant in operable CRC cancer patients."
I mean WTF - It was a great announcement ...and gave huge potential credibility to the B Cell Platform .....
extract from Recent IMU email response
PD1-Vaxx is in a Phase 1 trial, known asNeo-POLEM is an Investigator Sponsored Trial (IST) and will recruit patients insites in Australia and the UK. The trial is expected to recruit approximately44 patients with colorectal cancer. Treatment with PD1-Vaxx will beadministered before surgery (neoadjuvant). This study is expected to start in the first half of 2025.
( I note lots of people are dismissing the B Cell Platform - yet fundamentally It could replace a raft of legacy SoC treatments ...and without the onerous side effects - But it most like wont in the short term as Big Pharma has such a strong vested interest in their existing money train ...but thats another story )
Yet here it is now well over YEAR LATER ..... being spruiked ...and "about to get started .
I get it ...things can and do move at a snails pace ...and yes there is a lot happening
I'd actually like to see where the collaborating parties are at with this .
Investigator Sponsored Study (IST) clinical trial to be conducted by the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton in collaboration with Royal Surrey Hospital NHS Foundation Trust and The Australasian Gastro-Intestinal Trials Group (AGITG)
Meanwhile - Back to reality ....
Anyone who is dismissing C33 & Oncaralytics & Azercell as potential block buster therapies , is clearly a bit ignorant in my book .
Its a slow boat ..... yet the mission targets are mammoth .
Accordingly I still think the upside in IMU is huge .... and yet here we are hovering around 4 cents a share ....with so much progress being made .
Looking forward to good things & not fussed what others think
cheers
VA
GLTAH .... do what u reckon is a fair thing & whether people buy sell - or piss and moan ...I couldn't give a rats arse
LOL
- Forums
- ASX - By Stock
- Why IMU is a multi multi bagger
IMU
imugene limited
Add to My Watchlist
8.33%
!
1.1¢

There are a lot of moving part with IMU and some do appear to be...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
-0.001(8.33%) |
Mkt cap ! $82.13M |
Open | High | Low | Value | Volume |
1.2¢ | 1.3¢ | 1.1¢ | $376.2K | 32.83M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 3534042 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 11298051 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 369 | 0.012 |
29 | 5264798 | 0.011 |
101 | 26167538 | 0.010 |
35 | 12992890 | 0.009 |
9 | 1773622 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 1050600 | 4 |
0.012 | 12129374 | 24 |
0.013 | 12307192 | 26 |
0.014 | 8243651 | 32 |
0.015 | 7393152 | 29 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online